JP2014516080A - 一日一回の投与のための吸収が制御された水溶性の薬学的に活性な有機化合物製剤 - Google Patents

一日一回の投与のための吸収が制御された水溶性の薬学的に活性な有機化合物製剤 Download PDF

Info

Publication number
JP2014516080A
JP2014516080A JP2014514630A JP2014514630A JP2014516080A JP 2014516080 A JP2014516080 A JP 2014516080A JP 2014514630 A JP2014514630 A JP 2014514630A JP 2014514630 A JP2014514630 A JP 2014514630A JP 2014516080 A JP2014516080 A JP 2014516080A
Authority
JP
Japan
Prior art keywords
pharmaceutically active
particles
poly
polymer
particle diameter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2014514630A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014516080A5 (enExample
Inventor
デイビッド エフ． カウンツ，
ドナルド ピー． コックス，
アヌプ ケイ． ダム，
マイケル イー． スタルへイマー，
Original Assignee
エスティーアイ ファーマ， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エスティーアイ ファーマ， エルエルシー filed Critical エスティーアイ ファーマ， エルエルシー
Publication of JP2014516080A publication Critical patent/JP2014516080A/ja
Publication of JP2014516080A5 publication Critical patent/JP2014516080A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014514630A 2011-06-08 2012-06-07 一日一回の投与のための吸収が制御された水溶性の薬学的に活性な有機化合物製剤 Withdrawn JP2014516080A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161494659P 2011-06-08 2011-06-08
US61/494,659 2011-06-08
PCT/US2012/041331 WO2012170676A1 (en) 2011-06-08 2012-06-07 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017094634A Division JP2017137354A (ja) 2011-06-08 2017-05-11 一日一回の投与のための吸収が制御された水溶性の薬学的に活性な有機化合物製剤

Publications (2)

Publication Number Publication Date
JP2014516080A true JP2014516080A (ja) 2014-07-07
JP2014516080A5 JP2014516080A5 (enExample) 2015-05-28

Family

ID=47296440

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014514630A Withdrawn JP2014516080A (ja) 2011-06-08 2012-06-07 一日一回の投与のための吸収が制御された水溶性の薬学的に活性な有機化合物製剤
JP2017094634A Pending JP2017137354A (ja) 2011-06-08 2017-05-11 一日一回の投与のための吸収が制御された水溶性の薬学的に活性な有機化合物製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017094634A Pending JP2017137354A (ja) 2011-06-08 2017-05-11 一日一回の投与のための吸収が制御された水溶性の薬学的に活性な有機化合物製剤

Country Status (5)

Country Link
US (3) US10463611B2 (enExample)
EP (1) EP2717860A4 (enExample)
JP (2) JP2014516080A (enExample)
CA (1) CA2835293C (enExample)
WO (1) WO2012170676A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017137354A (ja) * 2011-06-08 2017-08-10 エスティーアイ ファーマ， エルエルシー 一日一回の投与のための吸収が制御された水溶性の薬学的に活性な有機化合物製剤
WO2022080798A1 (ko) * 2020-10-12 2022-04-21 뉴지랩테라퓨틱스 주식회사 나파모스타트 또는 이의 약제학적으로 허용가능한 염을 함유하는 방출 조절 제형 및 이의 제조방법
TWI765913B (zh) * 2016-09-27 2022-06-01 德商拜耳製藥公司 結晶型的考布曲鈣（ｃａｌｃｏｂｕｔｒｏｌ）及其製備方法

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
ES2742728T3 (es) 2009-07-22 2020-02-17 PureTech Health LLC Composiciones para el tratamiento de trastornos mejorados por la activación del receptor muscarínico
TWI649100B (zh) * 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
PL3024466T3 (pl) 2013-07-22 2018-08-31 Duchesnay Inc. Kompozycja do kontrolowania nudności i wymiotów
EP3218349A2 (en) 2014-11-14 2017-09-20 Gemphire Therapeutics Inc. Processes and intermediates for preparing , -dicarboxylic acid-terminated dialkane ethers
WO2017055935A1 (en) * 2015-09-30 2017-04-06 Symed Labs Limited Amorphous co-precipitates of flibanserin
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
CN106866546A (zh) * 2015-12-10 2017-06-20 常州爱诺新睿医药技术有限公司 氟班色林或其药学上可接受的盐与药用辅料的固体分散体及其制备方法
WO2018047002A1 (en) * 2016-09-12 2018-03-15 St Ip Holding Ag Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same
WO2018047013A1 (en) * 2016-09-12 2018-03-15 St Ip Holding Ag Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same
AU2017322544B2 (en) * 2016-09-12 2022-06-02 St Ip Holding Ag Formulations of 4-methyl-5-(pyrazin-2-yl)-3H-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same
EP3509642A1 (en) 2016-09-12 2019-07-17 ST IP Holding AG Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same
WO2018064490A1 (en) 2016-09-30 2018-04-05 Xenamed Corporation Compositions of midodrine and methods of using the same
EP3612171A4 (en) * 2017-04-18 2020-10-21 Gemphire Therapeutics Inc. GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND PROCEDURES FOR THE USE OF THE SAME
WO2019126770A1 (en) 2017-12-22 2019-06-27 Xenamed Corp. Extended release midodrine hydrochloride compositions and methods of use
PT3856182T (pt) 2018-09-28 2026-03-10 Karuna Therapeutics Inc Composições e métodos para o tratamento de perturbações melhoradas pela ativação dos recetores muscarínicos
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN114401716A (zh) * 2019-07-22 2022-04-26 纳诺米有限公司 持续释放的曲前列环素-化合物微粒组合物
PT4117638T (pt) * 2020-03-09 2026-07-16 Drotastar Llc Formulaes de libertao controlada compreendendo drotaverina ou sal da mesma
US11135220B1 (en) 2020-04-08 2021-10-05 St Ip Holding Ag Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione
CN117715632A (zh) 2021-03-09 2024-03-15 恩赛斯生物科学股份有限公司 包含酶可裂解的前药和萘莫司他的组合物及其使用方法
KR20230174213A (ko) 2021-03-09 2023-12-27 엔사이스 바이오사이언시즈 인크. 나파모스타트의 변형된 방출 조성물 및 그의 사용 방법

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63107917A (ja) * 1986-08-01 1988-05-12 エ−ピ−エス　リサ−チ　リミテツド イブプロフエン徐放性製剤およびその製造方法
JPH01250314A (ja) * 1987-10-22 1989-10-05 Aps Res Ltd 徐放性製剤
JPH05201867A (ja) * 1991-08-12 1993-08-10 Euro Celtique Sa スフェロイド製剤
US5431922A (en) * 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
WO2005046652A1 (en) * 2003-11-12 2005-05-26 Lek Pharmaceuticals D.D. Controlled release ketoprofen formulation
JP2006522099A (ja) * 2003-04-04 2006-09-28 ファルマシア コーポレーション 複合粒状体からなる経口徐放性圧縮錠
JP2007039353A (ja) * 2005-08-02 2007-02-15 Shionogi & Co Ltd 徐放性顆粒剤
JP2009019056A (ja) * 1998-10-01 2009-01-29 Elan Pharma Internatl Ltd 徐放性ナノ粒子組成物
US20100305163A1 (en) * 2009-05-20 2010-12-02 Pramod Dattatray Yedurkar Pharmaceutical formulations comprising nsaid and proton pump inhibitor drugs

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS521867A (en) 1975-06-24 1977-01-08 Tonichi Kotsu Consultant:Kk Rotary vertical garrage
JPS6327424A (ja) * 1986-07-17 1988-02-05 Shionogi & Co Ltd 徐放性製剤およびその製造法
US4971805A (en) * 1987-12-23 1990-11-20 Teysan Pharmaceuticals Co., Ltd. Slow-releasing granules and long acting mixed granules comprising the same
ES2177601T3 (es) * 1989-06-23 2002-12-16 Syntex Llc Ranolazina y pepeerazinas relacionadas para uso en el tratamiento de estados de choque. .
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
US5376384A (en) * 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
DK66493D0 (da) 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6528090B2 (en) * 1998-12-18 2003-03-04 Abbott Laboratories Controlled release formulation of divalproex sodium
FR2796790B1 (fr) 1999-07-23 2002-11-29 Sagem Procedes de transmission et de diffusion de paquets de donnees et recepteurs pour la mise en oeuvre des procedes
DK1411900T4 (da) 2001-06-01 2014-01-27 Pozen Inc Farmaceutiske sammensætninger til den koordinerede frigørelse af NSAIDs
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
US20040224020A1 (en) 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US20040219210A1 (en) * 2003-05-01 2004-11-04 Jian-Hwa Guo Controlled release solid dosage nifedipine formulations
US8389032B2 (en) * 2005-05-23 2013-03-05 Kraft Foods Global Brands Llc Delivery system for active components as part of an edible composition having selected particle size
US9161918B2 (en) * 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US20070184115A1 (en) 2005-12-30 2007-08-09 Biovail Laboratories International S.R.L. Modified release formulations of tramadol and uses thereof
US20070160667A1 (en) * 2006-01-11 2007-07-12 Nava Shterman Controlled release formulation of divalproex sodium
KR20100047190A (ko) * 2007-06-13 2010-05-07 오스펙스 파마슈티칼스, 인코포레이티드 치환 피페라진
US20100008986A1 (en) * 2008-07-14 2010-01-14 Glenmark Generics, Ltd. Pharmaceutical compositions comprising sumatriptan and naproxen
US20110313009A1 (en) * 2008-07-17 2011-12-22 Horizon Pharma Usa, Inc. Nsaid dose unit formulations with h2-receptor antagonists and methods of use
WO2010014502A1 (en) * 2008-07-31 2010-02-04 Aptapharma, Inc. Functionally coated breakable tablets
CA2835293C (en) * 2011-06-08 2020-08-18 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63107917A (ja) * 1986-08-01 1988-05-12 エ−ピ−エス　リサ−チ　リミテツド イブプロフエン徐放性製剤およびその製造方法
JPH01250314A (ja) * 1987-10-22 1989-10-05 Aps Res Ltd 徐放性製剤
US5431922A (en) * 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
JPH05201867A (ja) * 1991-08-12 1993-08-10 Euro Celtique Sa スフェロイド製剤
JP2009019056A (ja) * 1998-10-01 2009-01-29 Elan Pharma Internatl Ltd 徐放性ナノ粒子組成物
JP2006522099A (ja) * 2003-04-04 2006-09-28 ファルマシア コーポレーション 複合粒状体からなる経口徐放性圧縮錠
WO2005046652A1 (en) * 2003-11-12 2005-05-26 Lek Pharmaceuticals D.D. Controlled release ketoprofen formulation
JP2007039353A (ja) * 2005-08-02 2007-02-15 Shionogi & Co Ltd 徐放性顆粒剤
US20100305163A1 (en) * 2009-05-20 2010-12-02 Pramod Dattatray Yedurkar Pharmaceutical formulations comprising nsaid and proton pump inhibitor drugs

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017137354A (ja) * 2011-06-08 2017-08-10 エスティーアイ ファーマ， エルエルシー 一日一回の投与のための吸収が制御された水溶性の薬学的に活性な有機化合物製剤
TWI765913B (zh) * 2016-09-27 2022-06-01 德商拜耳製藥公司 結晶型的考布曲鈣（ｃａｌｃｏｂｕｔｒｏｌ）及其製備方法
WO2022080798A1 (ko) * 2020-10-12 2022-04-21 뉴지랩테라퓨틱스 주식회사 나파모스타트 또는 이의 약제학적으로 허용가능한 염을 함유하는 방출 조절 제형 및 이의 제조방법

Also Published As

Publication number Publication date
CA2835293C (en) 2020-08-18
US10463611B2 (en) 2019-11-05
US20140154313A1 (en) 2014-06-05
US20220047505A1 (en) 2022-02-17
US11191719B2 (en) 2021-12-07
EP2717860A4 (en) 2014-11-05
EP2717860A1 (en) 2014-04-16
WO2012170676A1 (en) 2012-12-13
US20200000719A1 (en) 2020-01-02
CA2835293A1 (en) 2012-12-13
JP2017137354A (ja) 2017-08-10

Similar Documents

Publication Publication Date Title
JP2017137354A (ja) 一日一回の投与のための吸収が制御された水溶性の薬学的に活性な有機化合物製剤
US8158152B2 (en) Lyophilization process and products obtained thereby
US7905852B2 (en) Skin-contacting-adhesive free dressing
US20240074995A1 (en) Methods and compositions for treating conditions associated with an abnormal inflammatory responses
US9016221B2 (en) Surface topographies for non-toxic bioadhesion control
JP2004514736A (ja) マトリクス上に分散する活性成分を含む医薬品
EP1212091B1 (en) Polyoxyalkylene copolymers containing pourable liquid vehicles
WO2023118074A1 (en) Compressible and free flowing co-processed mesoporous silica
World Health Organization The use of common stems in the selection of International Nonproprietary names (INN) for pharmaceutical substances: 2002

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150407

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150407

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170410

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20170612